After the Bell
Before the Bell
Jim Cramer's Daily Booyah
Winners & Losers
Australia's Mayne will shell out $652 million for a basket of generics products from Teva as the latter works to complete its pending Allergan generics purchase.
Trade-Ideas LLC identified Impax Laboratories (IPXL) as a "dead cat bounce" (down big yesterday but up big today) candidate
The deal helps the Israeli drug giant comply with required antitrust divestitures connected to completion of its $40.5 billion acquisition of the generics business of Allergan.
Impax Laboratories (IPXL) stock is plunging after the company agreed to buy a portfolio of generic drugs from Teva Pharmaceuticals (TEVA) and Allergan (AGN) for $586 million.
©1996-2016 TheStreet, Inc. All rights reserved.
Action Alerts PLUS is a registered trademark of TheStreet, Inc.